Data Insights

BNT-325 by Duality Biologics (Shanghai) for Epithelial Ovarian Cancer: Likelihood of Approval

BNT-325 is under clinical development by Duality Biologics (Shanghai) and currently in Phase II for Epithelial Ovarian Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - BNT-325 in Epithelial Ovarian Cancer

Data Insights

BNT-325 by Duality Biologics (Shanghai) for Peritoneal Cancer: Likelihood of Approval

BNT-325 is under clinical development by Duality Biologics (Shanghai) and currently in Phase II for Peritoneal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - BNT-325 in Peritoneal Cancer

Data Insights

BNT-325 by Duality Biologics (Shanghai) for Fallopian Tube Cancer: Likelihood of Approval

BNT-325 is under clinical development by Duality Biologics (Shanghai) and currently in Phase II for Fallopian Tube Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - BNT-325 in Fallopian Tube Cancer

Data Insights

DB-1310 by Duality Biologics (Shanghai) for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval

DB-1310 is under clinical development by Duality Biologics (Shanghai) and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC)....

Data Insights

DB-1312 by Duality Biologics (Shanghai) for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval

DB-1312 is under clinical development by Duality Biologics (Shanghai) and currently in Phase I for Squamous Non-Small Cell Lung Cancer....

Data Insights

DB-1312 by Duality Biologics (Shanghai) for Esophageal Cancer: Likelihood of Approval

DB-1312 is under clinical development by Duality Biologics (Shanghai) and currently in Phase I for Esophageal Cancer. According to GlobalData,...

Data Insights

DB-1312 by Duality Biologics (Shanghai) for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

DB-1312 is under clinical development by Duality Biologics (Shanghai) and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According...

Data Insights

DB-1312 by Duality Biologics (Shanghai) for Solid Tumor: Likelihood of Approval

DB-1312 is under clinical development by Duality Biologics (Shanghai) and currently in Phase I for Solid Tumor. According to GlobalData,...

Data Insights

DB-1312 by Duality Biologics (Shanghai) for Ovarian Cancer: Likelihood of Approval

DB-1312 is under clinical development by Duality Biologics (Shanghai) and currently in Phase I for Ovarian Cancer. According to GlobalData,...

Data Insights

DB-1312 by Duality Biologics (Shanghai) for Breast Cancer: Likelihood of Approval

DB-1312 is under clinical development by Duality Biologics (Shanghai) and currently in Phase I for Breast Cancer. According to GlobalData,...